Type 1 Diabetes Mellitus (DM)
Male 22 years of age ( Figure 1 [2] . In two studies from India, the prevalence of DR in type 2 diabetes patients were 34.1% and 37% [3] .WHO estimates -India has 31.7 million diabetic subjects at present. In USA, DR is the leading cause of new blindness in people 25-74 years of age. Approximately 700,000 persons have proliferative DR (PDR). Each year another 65,000 are diagnosed with the condition. A recent study has estimated that among people with diabetes aged 40 or older, 28.5% will develop DR. Worldwide 20 million people have PDR (very severe eye complication), with this number projected to increase to over 30 million by 2030. After 10 years of onset of DM, blindness was 1.8, 4.0 and 4.8% in type 1, insulin-treated type 2 and noninsulin-treated type 2 patients, respectively. In these three groups of patients, the 10-year incidence visual impairment (loss of 15 letters on a scale of 0-70 letters) was 9.4, 37.2 and 23.9%, respectively [4] . Good glycemic control arrests the development and progression of DR, but still there are a lot of factors that can influence the DR visual loss. Technological advances have improved the diagnostic accuracy of screening methods and given an access to the diabetic patients to the specialist care. In the last decades, the treatment strategies have been revised and besides laser photocoagulation, include surgical interventions and pharmacotherapies. DR will often go unnoticed when the condition is in its early stages but advanced symptoms can include blurred or sudden vision loss. Diabetics are advised to take advantage of the eye screenings which are offered free of charge in the UK, to detect any signs of the disease.
Correspondence: Tatjana.Josifova@usb.ch Ophthalmological Clinic, University of Basel, Switzerland Figure 1 Fundus photography of huge retinal bleeding and retinal detachment in PDR Stem cell research, especially the embryonic one, holds great promise in the search for a cure for type 1 diabetes and provide a powerful tool for controlling type 2 diabetes [5] . The first results of the stem-cells DR-treatment were presented at the ARVO in 2011. Patients experienced improvements in the function of the optic nerve, blood flow to the eye and reduction of inflammation in the six-month period following injection and became stable for the entire follow up period. To achieve our goals of personalized treatment, we need EU support in different projects that will connect the physicians with basic science investigations and biotechnology. In the overall economic downturn tremendous budget cuts will only lead to huge burden of diabetic complications treatment. 
